TY  - JOUR
A1  - Breun, Maria
A1  - Monoranu, Camelia M.
A1  - Kessler, Almuth F.
A1  - Matthies, Cordula
A1  - Löhr, Mario
A1  - Hagemann, Carsten
A1  - Schirbel, Andreas
A1  - Rowe, Steven P.
A1  - Pomper, Martin G.
A1  - Buck, Andreas K.
A1  - Wester, Hans-Jürgen
A1  - Ernestus, Ralf-Ingo
A1  - Lapa, Constantin
T1  - [\(^{68}\)Ga]-Pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas
JF  - Frontiers in Oncology
N2  - We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [\(^{68}\)Ga]Pentixafor.

Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [\(^{68}\)Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients.

Results: [\(^{68}\)Ga]Pentixafor PET/CT was visually positive in all cases. SUV\(_{mean}\) and SUV\(_{max}\) were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR\(_{mean}\) and TBR\(_{max}\) were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors.

Conclusion: Non-invasive imaging of CXCR4 expression using [\(^{68}\)Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.
KW  - vestibular schwannoma
KW  - CXCR4
KW  - PET/CT
KW  - molecular imaging
KW  - Pentixafor
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201863
VL  - 9
IS  - 503
ER  -